(S)-4-(2-(1-ethyl-1H-imidazol-4-yl)hydrazinyl)-5-fluoro-N-(1-(5-fluoropyridin-2-yl)ethyl)quinazolin-2-amine

ID: ALA4857672

PubChem CID: 164615240

Max Phase: Preclinical

Molecular Formula: C20H19F2N7

Molecular Weight: 395.42

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CCn1cnc(Nc2nc(N[C@@H](C)c3ccc(F)cn3)nc3cccc(F)c23)c1

Standard InChI:  InChI=1S/C20H19F2N7/c1-3-29-10-17(24-11-29)27-19-18-14(22)5-4-6-16(18)26-20(28-19)25-12(2)15-8-7-13(21)9-23-15/h4-12H,3H2,1-2H3,(H2,25,26,27,28)/t12-/m0/s1

Standard InChI Key:  JOHTXKRNXFDBDS-LBPRGKRZSA-N

Molfile:  

 
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
   26.5387   -9.9788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.0793   -9.9589    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.9355   -9.5470    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.1261   -9.4051    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.9487   -8.7906    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.2189  -10.3174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.7633   -8.6687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.8155   -9.5961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6539   -9.9518    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   30.0212  -13.6993    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   24.3595  -11.1902    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.6082  -12.0453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.0736  -10.7797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.0602  -12.4244    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.7716  -12.0224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.1923  -12.0352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6385  -12.4163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.9305  -12.0067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.3139  -13.2814    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.3188  -12.4562    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.8989  -12.4500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.7804  -11.1992    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.8890  -13.2687    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.5948  -13.6875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.9333  -11.1808    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3527  -12.0129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6481  -10.7726    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.1997  -11.2143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.4783  -12.4371    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  4  1  0
  2  8  1  0
  4  7  1  0
  4  3  1  0
  3  6  1  0
  7  5  2  0
  8  1  2  0
  5  8  1  0
 15 29  1  0
 27  9  1  0
 18 17  2  0
 23 24  1  0
 17 26  1  0
 20 12  2  0
 11 27  1  0
 19 10  1  0
 26 11  1  0
 16 21  1  0
 26 14  2  0
 13 11  2  0
 13  2  1  0
 22 13  1  0
 25 18  1  0
 21 23  2  0
 16 28  1  1
 15 22  2  0
 24 19  2  0
 29 16  1  0
 12 21  1  0
 27 25  2  0
 19 20  1  0
 14 15  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4857672

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 395.42

Molecular Weight (Monoisotopic): 395.1670

AlogP: 4.44

#Rotatable Bonds: 6

Polar Surface Area: 80.55

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.27

CX Basic pKa: 5.54

CX LogP: 4.11

CX LogD: 4.10

Aromatic Rings: 4

Heavy Atoms: 29

QED Weighted: 0.50

Np Likeness Score: -1.50

References

1. Uehling DE, Joseph B, Chung KC, Zhang AX, Ler S, Prakesch MA, Poda G, Grouleff J, Aman A, Kiyota T, Leung-Hagesteijn C, Konda JD, Marcellus R, Griffin C, Subramaniam R, Abibi A, Strathdee CA, Isaac MB, Al-Awar R, Tiedemann RE..  (2021)  Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma.,  64  (15.0): [PMID:34291633] [10.1021/acs.jmedchem.1c00506]

2. Tesmer, John J G JJ, Tesmer, Valerie M VM, Lodowski, David T DT, Steinhagen, Henning H and Huber, Jochen J.  2010-02-25  Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol.  [PMID:20128603]

Source

Source(1):

• Scientific Literature